Boston-based Odyssey Therapeutics completed an oversubscribed $218 million Series A round. The funds will be used to advance multiple programs from the company’s pipeline and discovery platform.
If you are not happy with the results below please do another search
50 search results for:
Shares of vTv Therapeutics climbed in trading on December 7 after the company announced plans to restructure and reduce head count by 65 percent in order to ensure funding for a Phase III trial for lead diabetes program TTP399.
Biopharmaceutical firm Alvotech Holdings announced merger plans with Oaktree Acquisition Corp. in a deal that will create a combined entity worth around $2.25 billion.
GSK said on December 7 the British drugmaker’s antibody-based Covid-19 therapy with U.S. partner Vir Biotechnology is effective against all mutations of the new Omicron coronavirus variant, citing new data from early-stage studies.
Fingerpaint, biopharma’s global commercialization partner for analytics-enabled integrated solutions, announced the acquisition of MedThink, a North Carolina–based company that empowers healthcare providers through medical communications.
Canadian drug developer Medicago’s plant-based Covid-19 vaccine candidate – enhanced by GlaxoSmithKline’s booster – was 75.3 percent effective against the Delta variant of the virus in a late stage study, the two companies said on December 7.
A major British study into mixing Covid-19 vaccines found that people had a better immune response when they received a first dose of AstraZeneca or Pfizer-BioNTech shots followed by Moderna nine weeks later, according to the results on December 6.
Survivors of previous infection with the virus that causes SARS-CoV-2 may be at higher risk for re-infection with the Omicron variant than with earlier versions of the virus, preliminary findings show. Additionally, a booster shot of the Pfizer/BioNTech Covid-19 vaccine appears to provide strong protection – at least in the short term – according to data from Israel.
Healthcare disruptions linked to the coronavirus pandemic helped malaria kill 69,000 more people in 2020 than the previous year, but a worst-case scenario was averted, the World Health Organization said on December 6.
Shares of Reata Pharmaceuticals were down nearly 40 percent the morning of December 6 after briefing documents released by the U.S. Food and Drug Administration revealed an unflattering opinion of the company’s experimental drug for Alport syndrome, bardoxolone.